▽The New England Journal of Medicine: Research & Review Articles on Diseases & Clinical Practice ●12/12 23:44 Dec 11, 2024San Antonio Breast Cancer SymposiumImlunestrant and CDK4/6 Inhibitor in Breast CancerK.L. Jhaveri and OthersThe selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone).Original ArticlePerspectiveAutopsy of a Drug
▽Health News & Medical News from Medical News Today ●12/12 06:02 NewsletterFind CommunityBezzy Breast CancerBezzy MSBezzy IBDBezzy PsoriasisHow too much fructose may feed cancer tumorsWritten by Corrie PelcPastries vs. sodas: Not all added sugars pose the same heart disease…Written by Jessica FreebornDiet rich in whole plant foods and fish may keep colon cancer at bayWritten by Paul Ian Cross, PhDEating more plant protein may lower the risk of heart